The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.

Marzano, A.V., Genovese, G., Casazza, G., Moltrasio, C., Dapavo, P., Micali, G., et al. (2020). Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study. BRITISH JOURNAL OF DERMATOLOGY [10.1111/bjd.18983].

Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study

Sirna, R;Patrizi, A;Dini, V;Bongiorno, M R;
2020-01-01

Abstract

The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.
2020
Marzano, A.V., Genovese, G., Casazza, G., Moltrasio, C., Dapavo, P., Micali, G., et al. (2020). Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study. BRITISH JOURNAL OF DERMATOLOGY [10.1111/bjd.18983].
File in questo prodotto:
File Dimensione Formato  
evidence for a window.pdf

Solo gestori archvio

Tipologia: Post-print
Dimensione 1.56 MB
Formato Adobe PDF
1.56 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/401854
Citazioni
  • ???jsp.display-item.citation.pmc??? 34
  • Scopus 84
  • ???jsp.display-item.citation.isi??? 82
social impact